Got $2,000? 2 Top Growth Stocks to Buy That Could Double Your Money.

Chewy: analysts forecast revenue growth of ~6% for fiscal 2025 and ~8% the following year, while the stock trades ~80% below pandemic highs with a trailing P/E of 52 and a forward P/E of 16, suggesting valuation-led upside if growth continues. Target: fiscal 2025 revenue was $105B (-2% Y/Y) and net income was $3.7B (-9% Y/Y); the company is planning a $5B store and operations investment under new CEO Michael Fiddelke, forecasts ~2% sales growth for fiscal 2026, yields a $4.56 annual dividend (3.9%), and trades at a P/E of ~14 versus Walmart at ~46. Both names are presented as value/recovery plays where improving fundamentals and lower valuations could permit significant upside, but execution and demand recovery remain risks.

Analysis

Chewy’s progress is less a pure top-line story and more a rolling change in revenue mix that creates optionality on gross-margin capture and customer LTV; the second-order winners are specialty pet pharma manufacturers and third-party logistics networks that can monetize higher-frequency, higher-margin SKUs. If pharmacy/recurring revenue scales to a mid-double-digit share of sales, working-capital and inventory mix will shift materially (higher AR/seasonality) and create a visible margin inflection that could re-rate the stock ahead of absolute revenue reacceleration.

Target’s opportunity is classic brick-and-mortar remediation: store-level productivity gains and assortment resets can translate into outsized EPS leverage because fixed cost absorption and reduced markdown-driven gross margin erosion compound over multiple years. However, the path is lumpy — remodel-driven capex and a multi-quarter inventory reset can depress near-term free cash flow even as unit economics improve, leaving the stock sensitive to execution cadence and consumer discretionary elasticity in slower macro regimes.

The consensus frames both names as single-factor recovery trades; what’s under-appreciated is cross-channel market share flow and supplier pricing power. If Chewy squeezes vet/retail margins, expect competitors to respond with promo intensity that temporarily compresses margins industry-wide. Conversely, if Target’s store productivity improvements beat by a few hundred basis points versus expectations, the valuation gap to peers could compress quickly, producing concentrated upside within 12–24 months while downside remains execution and macro correlated.

Key Decisions for Investors

• Long TGT (size 1.5–3% AUM): buy outright with 12–24 month horizon to capture store productivity re-rating. Target a 50–80% upside if comp/margin inflection appears within 12 months; use a 20% stop-loss to limit execution risk.
• Long CHWY via defined-risk options (size 0.5–1% AUM): buy a 9–12 month call spread with long strike ~25–35% above current level and short a further OTM strike to fund cost. Thesis: asymmetric payoff if pharmacy/recurring mix re-rates margins; max loss = premium, target 3x+ return if catalyst materializes.
• Pair trade to isolate specialty re-rate: long CHWY / short AMZN (notional ratio ~1:0.35) over 6–12 months. This reduces market-beta and isolates pet-retail re-rating; close if CHWY/AMZN ratio reverts by 15% or after 12 months.
• Event hedge: buy short-dated puts on both names (6–9 months, modest size) around earnings windows to protect against missed execution. These limit tail risk from inventory shocks or an unexpected macro slowdown while allowing upside participation.